News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Brian Ellman, MBA

Articles by Brian Ellman, MBA

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
Published: October 21st 2016 | Updated:

Trending on AJMC

Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets

Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc

Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes

Visceral Adiposity May Explain Much of CKD Seen in Older Adults With HFpEF

Bridging the Academic-Community Gap in Cancer Care: Andrew Yee, MD